Embarking on a Trailblazing Journey: Celularity and Regeneron Join Forces in a Multi-Year Research Collaboration Services Agreement

“Unlocking the Future of Cell Therapies: Celularity Teams Up with Regeneron in Groundbreaking Research Partnership

FLORHAM PARK, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) — Brace yourselves for a revolutionary collaboration! Celularity Inc. (Nasdaq: CELU), a trailblazing biotech company at the forefront of allogeneic cell therapies, has just unveiled an exciting new chapter. In a visionary move, Celularity is teaming up with Regeneron Pharmaceuticals, Inc. (Regeneron), a powerhouse in the pharmaceutical realm, through a game-changing multi-year Research Collaboration Services Agreement. The goal? To elevate the research efforts surrounding Regeneron’s allogeneic cell therapy candidates.

Beneath the spotlight of this dynamic partnership is the cutting-edge exploration of a targeted allogeneic gamma delta chimeric antigen receptor (CAR) T-cell therapy, masterminded by Regeneron. What’s it all about? This therapy aims to supercharge proliferation and potency against formidable solid tumors. And where will this transformative research unfold? None other than Celularity’s state-of-the-art facility nestled in Florham Park, N.J. As for the financial intricacies of this groundbreaking venture, the details remain tantalizingly under wraps.

Robert J. Hariri, M.D., Ph.D., the trailblazing CEO, Chairman, and Founder of Celularity, heralds this agreement with Regeneron as a pivotal moment. A true recognition of Celularity’s prowess in cellular therapy research, especially in the realm of engineering CAR-T cells. Hariri’s words resonate with excitement:

“This partnership with Regeneron marks a significant milestone for Celularity, underscoring our expertise in cellular therapies and CAR-T cell engineering. It opens the door to potential future collaborations, harnessing our world-class cell therapy facilities and capabilities. The Regeneron team’s legacy of scientific excellence is something we deeply admire, and we’re thrilled to unite with such a global leader in pioneering medicines.”

About Celularity

Pioneering the Future of Medicine: Celularity Inc. (Nasdaq: CELU), headquartered in the vibrant hub of Florham Park, N.J., stands as a biotechnology trailblazer, spearheading the dawn of a new era in cellular and regenerative medicine. Imagine a world where healing comes from within, where science taps into the incredible power of the human placenta. Celularity is making that vision a reality by crafting allogeneic cryopreserved off-the-shelf placental-derived cell therapies that hold the promise of revolutionizing healthcare.

Picture this: mesenchymal-like adherent stromal cells (MLASCs) stepping up to the plate, CAR T-cells driving innovation to new heights, and both genetically modified and unmodified natural killer (NK) cells unleashing their potential—all hailing from the placenta. These game-changing therapeutic programs, meticulously crafted by Celularity, target a wide range of conditions, from autoimmune and infectious diseases to degenerative ailments and cancer.

But Celularity’s visionary journey doesn’t stop there. Drawing inspiration from the postpartum placenta, Celularity is also in the business of crafting innovative biomaterial products that hold the potential to change lives. With the placenta’s unique biology at their fingertips, Celularity is on a mission to redefine the landscape of therapeutic solutions. The goal? To shatter barriers, offering effective, accessible, and affordable therapies that cater to the unmet needs of our global community.

Celularity’s Forward-Looking Statements

Unlocking the Future: This press release ventures into the realm of ‘forward-looking statements,’ navigating the landscape defined by The Private Securities Litigation Reform Act of 1995, as well as the dynamic terrain of the Securities Act of 1933 and the Securities Exchange Act of 1934. Beyond the confines of historical facts, we delve into the realm of anticipation, belief, potential, and more.

Imagine the possibilities: words like ‘anticipate,’ ‘contemplate,’ and ‘project’ guide us into the uncharted waters of what’s to come. With an eye on the horizon, we explore the research collaboration services agreement with Regeneron, envisioning the benefits that may unfold through this collaboration. Yet, as with any journey, there are hurdles to overcome. The intricate dance of biotechnological development, intertwined with economic fluctuations and supply chain complexities, creates a dynamic backdrop.

Our journey through these uncharted territories is marked by resilience and adaptability. The very essence of these ‘forward-looking statements’ rests on the synergy between Celularity’s aspirations and the ever-evolving reality. The road ahead is shaped by factors both known and unforeseen, stretching beyond what we grasp today.

Like a compass pointing to unexplored destinations, this press release does not merely encapsulate a snapshot in time. It is a living narrative, shifting with the tides of innovation, knowledge, and circumstance. As we continue to chart new courses, these forward-looking statements stand as a testament to our vision, a vision that continually evolves, always seeking to unlock the potential of what lies ahead. While the path may twist and turn, our commitment remains steadfast—to update, refine, and illuminate, as we collectively shape the future we envision.

Leave a Comment